To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 1997

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2008

Conditions
Psoriasis
Interventions
DRUG

Daclizumab

Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.

DEVICE

NB-UVB

total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.

Trial Locations (3)

10021

Rockefeller University Hospital, New York

Rockefeller University, New York

10065

Rockefeller University, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Facet Biotech

INDUSTRY

lead

Rockefeller University

OTHER